COMPOSITION FOR CULTURING NK CELLS AND METHOD FOR CULTURING NK CELLS USING SAME

Abstract

Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.

Claims

1. A composition for culturing natural killer cells (NK cells), the composition comprising IL-15, 1L-18, IL-27, or a combination thereof.

2. The composition of claim 1, further comprising insulin-transferrin-selenium (ITS).

3. The composition of claim 1, wherein the culturing is for proliferating or activating NK cells.

4. The composition of claim 1, wherein, in the cell culture medium, a concentration of IL-15 is 0.1 ng/ml to 1000 ng/ml, a concentration of IL-18 is 0.25 ng/ml to 2500 ng/ml, and a concentration of IL-27 is 0.20 ng/ml to 2000 ng/ml.

5. The composition of claim 1, wherein the NK cells have surface antigen characteristics of CD3.sup.− and CD56.sup.+.

6. A method of culturing natural killer cells (NK cells), the method comprising culturing the NK cells in a composition for culturing NK cells, the composition comprising IL-15, IL-18, and IL-27.

7. The method of claim 6, further comprising: before the culturing, obtaining peripheral blood mononuclear cells (PBMCs) from peripheral blood; and isolating NK cells from the obtained PBMCs.

8. The method of claim 6, wherein the culturing is performed for 7 days to 30 days.

9. NK cells prepared by the method of claim 6.

10. A method of preventing or treating cancer, the method comprising administering an effective amount of NK cells prepared by the method of claim 6.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0039] FIG. 1 shows results of counting the numbers of PBMCs and NK cells isolated from healthy normal individuals;

[0040] FIG. 2A shows FACS results of analyzing phenotypes of NK cells immediately (D0) after isolating the NK cells from PBMCs isolated from healthy normal individuals and 21 days (D21) after culturing the NK cells;

[0041] FIG. 2B shows results of analyzing distributions of CD3.sup.−CD56.sup.+ NK cells immediately (D0) after isolating PMBCs and NK cells from healthy normal individuals and 21 days (D21) after culturing the PMBCs and NK cells;

[0042] FIG. 2C shows results of calculating the purity of NK cells immediately (D0) after isolating the NK cells from PBMCs isolated from healthy normal individuals and 21 days (D21) after culturing the NK cells;

[0043] FIG. 3A shows photographs showing results of culturing NK cells for 3 days (Day 3), 7 days (Day 7), 17 days (Day 17), and 21 days (Day 21) in the composition for culturing NK cells of the present disclosure;

[0044] FIG. 3B shows graphs showing the numbers of NK cells cultured for 3 days (Day 3), 7 days (Day 7), 17 days (Day 17), and 21 days (Day 21) in the composition for culturing NK cells of the present disclosure;

[0045] FIG. 3C shows a graph showing proliferation of NK cells on day 0 (D0), day 3 (D3), day 13 (D13) and day 21 (D21) according to cytokine cocktails;

[0046] FIG. 4 shows results of examining effects of the composition for culturing NK cells of the present disclosure on NK cell activity;

[0047] FIG. 5A shows photographs of NK cells cultured for 21 days in a culture medium containing IL-2; IL-15 and IL-18 (IL-15/18); or IL-15, IL-18, and IL-27 (IL-15/18/27), with ITS (+ITS) or without (−ITS);

[0048] FIG. 5B shows a graph showing the number and proliferation of NK cells as a result of culturing using 6-well plates for 0-5 days, culturing using T25 flasks for 5-12 days, and then culturing for 21 days after transferring to T75 flasks on day 21;

[0049] FIG. 5C shows results of examining cell viability of NK cells when the NK cells are cultured as in FIG. 5B;

[0050] FIG. 6A shows a photograph showing morphology of NK cells when cultured using a mixed culture medium of cytokines IL-15, IL-18, and IL-27 and ITS;

[0051] FIG. 6B shows graphs showing a growth curve and proliferation of NK cells when cultured using a mixed culture medium of cytokines IL-15, IL-18, and IL-27 and ITS;

[0052] FIG. 6C shows a graph showing viability of NK cells when cultured using a mixed culture medium of cytokines IL-15, IL-18, and IL-27 and ITS;

[0053] FIG. 7 shows results of examining cancer cell cytotoxicity of NK cells cultured by adding the composition for culturing NK cells of the present disclosure;

[0054] FIG. 8 shows a graph showing ELISA results of examining IFN-γ secreted from NK cells on day 7 (D7), day 14 (D14), and day 21 (D21) following culture;

[0055] FIG. 9 shows results of examining cancer cell cytotoxicity of NK cells cultured by adding the composition for culturing NK cells of the present disclosure;

[0056] FIG. 10 shows results of examining activity, expression patterns, and expression levels of caspase-3 in cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure; and

[0057] FIG. 11 shows images of expression levels and expression locations of caspase-3 in cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure.

MODE OF DISCLOSURE

[0058] Hereinafter, the present disclosure will be described in more detail with reference to exemplary embodiments. However, these exemplary embodiments are only for illustrating the present disclosure, and the scope of the present disclosure is not limited to these exemplary embodiments.

EXAMPLE 1

Isolation of Natural Killer (NK) Cells and Examination of Proliferative Capacity of NK Cells, Activity of NK Cells, and Cytotoxicity of NK Cells Against Cancer Cells, After Culturing NK Cells Using Composition for Culturing NK Cells

[0059] 1. Isolation of NK cells and Culturing of NK cells using Composition for Culturing NK Cells

[0060] (1.1) Selection of research subjects, Isolation of blood and PBMCs, and Isolation of NK cells

[0061] Healthy males and females aged 20 to 65 years were subjects who agreed to blood collection for this study, and subjects eligible to participate in this study were selected based on health questionnaire, body weight, and vital signs. Subjects eligible to participate in the study were selected by the following criteria.

[0062] 1) Those who do not have the following exclusions through health questionnaire

[0063] Those with a history of cardiovascular diseases such as hypertension, etc., kidney disease, diabetes, and cancer

[0064] Those who refuse blood transfusion for religious reasons, etc.

[0065] Pregnant women

[0066] 2) Males having body weight of 50 kg or more and females having body weight of 45 kg or more

[0067] 3) Those who satisfy the following vital signs

[0068] Blood pressure (mmHg): systolic pressure of 90 to 179 and diastolic pressure of less than 100

[0069] Body temperature (° C.): 37.5° C. or less

[0070] Pulse (beats/min): 50 to 100

[0071] On the day of visit, a total of 100 ml of blood was collected in a tube containing heparin once from those selected as research subjects, respectively.

[0072] From the collected blood, peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (GE Healthcare, 17-1440-02) by the following method. The collected whole blood was diluted 1:1 with phosphate buffered saline (PBS) (pH 7.4, Thermo Fisher Scientific), and the diluted blood was carefully added to the top of Ficoll. Subsequently, centrifugation was performed at 2500 rpm and 25° C. for 22 minutes to isolate PBMCs. The isolated PBMCs were washed with PBS. Thereafter, PBMCs without any treatment were stored before isolation of NK cells. Further, plasma obtained during the isolation process was also collected and stored.

[0073] From the isolated PBMCs, NK cells were isolated using an NK cell isolation kit (Miltenyi Biotec, 130-092-657) and CD3.sup.+ magnetic beads (Miltenyi Biotec) by the following method, and CD3.sup.+ cells were removed. MACS running buffer (PBS, 2 mM EDTA, 0.5% BSA) was added to the isolated PBMCs in a volume of 40 μl per 1×10.sup.7 cells to suspend PBMC cell pellets, and then CD3.sup.+ magnetic beads were added in a volume of 20 μl per 1×10.sup.7 cells and allowed to react at 4° C. for 10 min. Subsequently, the cells were washed with MACS buffer, and then CD3.sup.−CD56.sup.+ NK cells were recovered using a MACS cell separator (Miltenyi Biotec).

[0074] FIG. 1 and Table 1 show results of counting the numbers of PBMCs and NK cells isolated from healthy normal individuals. FIG. 1 shows results of counting the number of PBMCs isolated from healthy normal individuals and the number of NK cells isolated from healthy normal individuals. As shown in FIG. 1 and Table 1, distribution of the CD3.sup.−CD56.sup.+ NK cells in PBMCs in the blood was about 8% to about 20% on average. There was no difference according to gender, and there was no statistically significant increase or decrease in NK cells according to age.

TABLE-US-00001 TABLE 1 Age Number of healthy Average (Mean ± SD) Gender (years) normal individuals PBMC(×10.sup.8) NK(×10.sup.7) Female 20-29 5 2.564 ± 0.952 2.526 ± 1.259 30-39 5 1.634 ± 0.461 1.220 ± 0.139 40 2 1.952 ± 1.294 2.455 ± 0.955 Total 12 Male 20-29 2 2.385 ± 0.587 2.425 ± 0.955 30-39 9 1.965 ± 0.579 2.294 ± 1.264 40-49 3 1.237 ± 0.220 2.100 ± 0.383 Total 14

[0075] Subsequently, whether NK cells in the isolated PBMCs and the collected NK cells had CD3.sup.−CD56.sup.+ characteristics was examined by fluorescence activated cell sorting (FACS, BD FACSCalibur).

[0076] FIG. 2 shows FACS results of analyzing phenotypes of NK cells in PBMCs isolated from healthy normal individuals and the collected NK cells. FIG. 2A shows the results of analyzing phenotypes of NK cells immediately (D0) after isolating the NK cells and 21 days (D21) after culturing the NK cells. FIG. 2B shows results of analyzing distributions of CD3.sup.−CD56.sup.+ NK cells immediately (D0) after isolating PMBCs and NK cells and 21 days (D21) after culturing the PMBCs and NK cells.

[0077] Referring to FIG. 2, NK cells (CD3.sup.−CD56.sup.+) collected from healthy normal individuals (#8) had purity of 95% or more, and distributions of T cells, B cells, and monocytes were about 1% to about 2%. NK cells (D21) after culture for 21 days had purity of 98% or more.

[0078] (1.2) Culture of NK Cells Using Composition for Culturing NK Cells

[0079] NK cells obtained in (1) were added at a density of 1×10.sup.5 cells/ml in each well of a 12- or 24-well tissue culture plate, and CellGro® serum-free medium (CellGenix, USA), 10% human serum (Sigma Aldrich, USA), 10,000 U/mL penicillin/streptomycin (Pen/Strep) (Gibco/Life Technologies, Carlsbad, Calif.), cytokine (IL-15, IL-27, 1-100 ng/ml; Peperotech, Inc. NJ, USA; IL-18, 1-100 ng/ml; R&D Systems, Inc., MN, USA), and ITS (Insulin-Transferrin-Selenium-G Supplement 100×, Gibco™) were added thereto, followed by culturing in an incubator at 37° C. and 5% CO.sub.2 for 21 days.

[0080] In detail, 4 sets of cytokine combination treatment groups including a combination treatment group 1-1: IL-7 (5 ng/ml), IL-15 (10 ng/ml), IL-18 (25 ng/ml), IL-21 (5 ng/ml), and IL-27 (20 ng/ml), a combination treatment group 1-2: IL-15 (10 ng/ml), IL-18 (25 ng/ml), IL-21 (5 ng/ml), and 1L-27 (20 ng/ml), a combination treatment group 1-3: IL-15 (10 ng/ml), IL-18 (25 ng/ml), and IL-27 (20 ng/ml), and a combination treatment group 1-4: IL-15 (10 ng/ml) and IL-18 (25 ng/ml) were mixed in a fresh medium, respectively, and then, once every 2 to 3 days, which is the time to replace the medium, the medium was added to the NK cells during culture, and cultured. Compositions of the media are the same as described above, except for cytokines.

[0081] FIG. 2C shows results of analyzing the purity of NK cells immediately (D0) after isolating the NK cells and 21 days (D21) after culturing the NK cells. According to FIG. 2C, NK cells collected from the healthy normal individuals (#8) were found to have the purity of about 95% or more, even after cultured by adding the composition for culturing NK cells of the combination treatment group 1-3.

[0082] 2. Examination of Proliferative Capacity of NK Cells and Activity of NK Cells After Cultured by Adding Composition for Culturing NK Cells

[0083] (2.1) Examination of Proliferative Capacity of NK Cells After Cultured by Adding Composition for Culturing NK Cells

[0084] The number NK cells proliferated during culture as in (1.2) was increased, starting from 1×10.sup.5 cells/ml to 1×10.sup.6 cells/ml of NK cells in a 6-well tissue culture plate to a large amount in T25, T75, and BAG (NIPRO cell culture bags, A-1000NL, A-350NL, Funakoshi Co., Ltd.) at intervals of 2 days to 3 days. Viability was determined using a hemocytometer after staining the propagated NK cells with a trypan blue staining agent (Thermo Fisher Scientific, USA).

[0085] FIG. 3 shows results of examining the effect of the composition for culturing NK cells of the present disclosure on proliferation and viability of NK cells. FIG. 3A shows photographs showing results of culturing NK cells for 3 days (Day 3), 7 days (Day 7), 17 days (Day 17), and 21 days (Day 21) in the composition for culturing NK cells of the present disclosure. As shown in FIG. 3A, when NK cells were cultured (stimulated) by adding the combination treatment group 1-3 among the compositions for culturing NK cells of the present disclosure, primary NK cells grew continuously while forming clusters, and their cell viability was as high as about 85% to about 90% on average for 21-day culture. FIG. 3B shows graphs showing the numbers of NK cells. As shown in FIG. 3B, the number of the NK cells of healthy normal individuals (#12) showed about 26 times increase from about 6×10.sup.6 cells to 1.58×10.sup.8 cells, after cultured for 21 days by adding the combination treatment group 1-3, as compared with those before culture. Further, the number of the NK cells of healthy normal individuals (#2) showed about 40 times and about 53.3 times increase, after cultured by adding the combination treatment group 1-2 and the combination treatment group 1-3, respectively. FIG. 3C shows a graph showing proliferation of NK cells on day 0 (D0), day 3 (D3), day 13 (D13) and day 21 (D21) according to cytokine cocktails. As shown in FIG. 3C, the proliferation of NK cells showed the significantly increased number of cells, when cultured for 21 days by adding the combination treatment group 1-3. Small differences between normal individuals were observed.

[0086] (2.2) Examination of Activity of NK Cells After Cultured by Adding Composition for Culturing NK Cells

[0087] During culture as in (1.2), differences in activity of NK cells and receptor expression were examined.

[0088] During culture of NK cells, NK cells were collected, and 1×10.sup.5 NK cells were dispensed in a FACS tube (Falcon® 5 mL Round Bottom Polystyrene Test Tube). An antibody of a target gene was added to the FACS tube, and allowed to react for 30 min. Thereafter, washing was performed using FACS buffer, and surface antigen characteristics were analyzed using fluorescence-activated cell sorting (FACS, BD FACSCalibur™). FlowJo program was used for data analysis.

TABLE-US-00002 Target gene Company Cat. CD3 APC BD 555342 CD3 PE Invitrogen 12-0038-42 CD56 FITC BD 562794 CD56 PE BD 555516 Activating receptor CD314/NKG2D PE Thermo 12-5878-42 CD335 PE BD 557991 CD336 PE BD 558563 CD337 PE BD 558407 CD226 (DNAM) PE BD 559789 Inhibitor receptor NKG2A PE R&D FAB1059P KIR2DL4 (CD158d) PE R&D FAB2238P-100 KIR2DL5A (CD158f1) PE Origene AM26776RP-N KIR2DL1/158a FITC BD 556062 KIL2DL2/3 158b FITC BD 559784 KIR3DL1 (CD158e1, NKB1) FITC BD 555966 KIR3DL2 PE R&D FAB2878P-100 KIR3DL3 (CD158z) Alexa 647 R&D FAB8919R-025 Surface marker CD14 PE BD 555398 CD19 FITC BD 555412 CD69 PE Invitrogen MHCD6904/ 1701544A CD96 PE BD 562379 CD16 PE Thermo MHCD1604

[0089] FIG. 4 shows results of examining effects of the composition for culturing NK cells of the present disclosure on NK cell activity. Referring to FIG. 4, an expression level of CD226 which is one of activating receptors on NK cells was increased from about 12.3% to about 95.7%, after cultured by adding the combination treatment group 1-3 (D21), as compared with those before culture (D0). Further, an expression level of CD69 which is an activation index was increased from about 3.3% to about 91.4%, after cultured by adding the combination treatment group 1-3 (D21), as compared with those before culture (D0). It was found that a large quantity of NK cells may be induced and proliferated only by using a small number of cytokines without feeder cells.

[0090] (2.3) Examination of NK Cell Proliferation Effect of ITS Addition

[0091] It was examined whether NK cell proliferation effect may be increased by adding insulin-transferrin-selenium (ITS) during culture of NK cells. NK cells were cultured for 21 days in three different culture media, each containing IL-2; IL-15 and IL-18; or IL-15 and IL-18 and IL-27 with or without ITS (Insulin-Transferrin-Selenium-G Supplement 100×, Gibco™). The results of culture are shown in FIG. 5.

[0092] FIG. 5A shows photographs of NK cells cultured for 21 days in a culture medium containing IL-2; IL-15 and IL-18 (IL-15/18); or IL-15, IL-18 and IL-27 (IL-15/18/27) with ITS (+ITS) or without (−ITS).

[0093] As shown in FIG. 5A, when ITS was added to the culture medium containing IL-2; IL-15 and IL-18; or IL-15 and IL-18 and IL-27, NK cells were more actively proliferated to form clusters, indicating a synergistic effect.

[0094] FIG. 5B shows a graph showing the number and proliferation of NK cells as a result of culturing using 6-well plates for 0-5 days, culturing using T25 flasks for 5-12 days, and then culturing for 21 days after transferring to T75 flasks on day 21.

[0095] As shown in FIG. 5B, in the NK cell proliferation, improvement in NK cell proliferation by ITS was observed. When treated with only IL-15/IL-18/IL-27, 13.76 times increase (2.064×10.sup.7) was observed, as compared with the initial. In contrast, when cultured with a mixture of IL-15/IL-18/IL-27 and ITS, 27.88 times increase (4.1825×10.sup.7) was observed.

[0096] FIG. 5C shows results of examining cell viability when the cells were cultured as above.

[0097] As shown in FIG. 5C, both two cells showed viability of 95% or more and cluster formation. Therefore, it was found that use of ITS does not influence cell viability.

[0098] Taken together, it was confirmed that addition of ITS may further improve the NK cell proliferation effect in the composition of culturing NK cells of the present disclosure.

[0099] (2.4) Examination of NK Cell Culture in Culture Bag

[0100] It was examined whether the method of culturing NK cells as confirmed above may be applied to mass-production of NK cells. In detail, NK cells obtained from the same subjects were activated using IL-15/18/27 early on days 0-7, and then ITS was added to the existing NK cell culture medium, followed by culture in a T25 plate. On days 7-12, the cells were transferred to several T25 plates, followed by culture. After 12-14 days of culture, the cells were transferred to a culture bag, followed by culture for 21 days.

[0101] FIG. 6 shows a photograph of NK cells cultured in the culture bag.

[0102] FIG. 6A shows a photograph showing morphology of NK cells when cultured using a mixed culture medium of cytokines IL-15, IL-18, and IL-27 and ITS.

[0103] FIG. 6B shows graphs showing a growth curve and proliferation of NK cells when cultured using a mixed culture medium of cytokines IL-15, IL-18, and IL-27 and ITS.

[0104] As shown in FIGS. 6A and 6B, NK cells also formed clusters in the culture bag, as in the culture of using the plate. Further, cell growth was increased to 2.84×10.sup.8, which was about 31.53 times, as compared with the initial number of NK cells, indicating continuous growth for 21 days.

[0105] FIG. 6C shows a graph showing viability of NK cells when cultured using a mixed culture medium of cytokines IL-15, IL-18, and IL-27 and ITS.

[0106] As shown in FIG. 6C, high cell variability of 98% or more was observed.

[0107] Therefore, when NK cells were cultured using the composition for culturing NK cells according to the present disclosure, the NK cell proliferation effect was observed not only in the plate but also in the culture bag, indicating that the composition may also be applied to mass-production.

[0108] 3. Examination of Cytotoxicity of NK Cells Against Cancer Cells Using Composition for Culturing NK Cells

[0109] (3.1) Examination of Cancer Cell Cytotoxicity of NK Cells Cultured by Adding Composition for Culturing NK Cells 1

[0110] (3.1.1) Cytotoxicity Assay

[0111] Cytotoxicity assay was performed for K562 cell (human chronic myelogenous leukemia cell line), which is generally used for measuring NK cell activity because of high sensitivity to NK cells, using a CytotTox-Glo™ cytotoxicity assay kit of Promega. This assay is a method of measuring an enzyme released as a result of cell membrane damage, in which enzymatic reaction of dead cells may be measured by examining a luminogenic peptide substrate (alanyl-alanyl-phenylalanyl-aminoluciferin, AAF-Glo Substrate).

[0112] K562 cells were dispensed at a density of 1×10.sup.4 cells in each well of a 96-well plate coated with poly-D-lysine, and NK92 and NK cells for cytotoxicity assay were added thereto at an E:T ratio of 0:1, 1.25:1, 2.5:1, 5:1, or 10:1, and allowed to react for 4 hr. Thereafter, 50 μL of CytotTox-Glo™ cytotoxicity assay reagent was added and allowed to react at room temperature for 15 min, and then enzymatic activity of dead cells was measured using a luminometer. Subsequently, 50 μL of lysis buffer was added and allowed to react for 15 min, and then the total number of cells was examined. A percentage of the dead cells to the total number of cells was calculated to analyze cytotoxicity. At this time, the obtained data were analyzed using Microsoft Excel and GraphPad Prism 5.0.

[0113] FIG. 7 shows results of examining cancer cell cytotoxicity of NK cells cultured by adding the composition for culturing NK cells of the present disclosure. Referring to FIG. 7, when cells were cultured using IL-2 alone, IL-15 alone, IL-15 and IL-18 (IL-15/18), IL-15 and IL-27 (IL-15/27), IL-18 and IL-27 (IL-18/27), or IL-15, IL-18 and IL-27 (IL-15/18/27), remarkably increased NK cytotoxicity was observed on day 7 (D7), day 14 (D14), and day 21 (D21) in NK cells cultured using a combination of two or more cytokines, as compared with those cultured using cytokine alone. In particular, when cultured using a combination of IL-15, IL-18, and IL-27, the highest cytotoxicity was maintained even during long-term (21 days) culture of NK cells. In a comparative experiment using an NK-92 cell line, the cytotoxicity assay value (RLU) of the NK cells was also 2 time or higher than that of NK-92. These results indicate that cancer cell cytotoxicity of NK cells stimulated with a combination of IL-15, IL-18, and IL-27 was further increased, as compared with those stimulated with IL-2 or IL-15 alone.

[0114] Additionally, cytotoxicity was also examined by measuring changes in expression of IFN-γ secreted by NK cells. In detail, during NK cell culture, 1 ml of NK cell culture medium was collected every 7 days. In the collected culture media, IFN-γ expression was measured using an enzyme-linked immunosorbent assay (ELISA, R&D, MN, USA), and results were analyzed using an ELISA Microplate Reader, and shown in FIG. 8.

[0115] FIG. 8 shows a graph showing ELISA results of examining IFN-γ secreted from NK cells on day 7 (D7), day 14 (D14), and day 21 (D21) following culture.

[0116] As shown in FIG. 8, when treated with IL-2 alone, IL-15 alone, IL-15 and IL-18 (IL-15/18), IL-15 and IL-27 (IL-15/27), or IL-15, IL-18, and IL-27 (IL-15/18/27), a high expression level of IFN-γ secreted by NK cells was observed in the IL-15/18/27-treated group, as compared with other cytokine-treated groups.

[0117] Therefore, stimulation of NK cells with cytokines effectively activated immune cells present in blood, leading to IFN-γ secretion. Further, since this result shows a significant relationship with the cytotoxicity result of NK cells, measurement of the IFN-γ secretion capacity of NK cells may represent cytotoxicity of NK cells.

[0118] (3.2.2) Calcein AM Assay

[0119] K562 cells stained with Calcein AM (Thermo Fisher Scientific) were dispensed at a density of 1×10.sup.5 cells in each well of a 6-well plate coated with poly-D-lysine, and NK92 and NK cells for cytotoxicity assay were added thereto at an E:T ratio of 0:1, 1.25:1, 2.5:1, 5:1, or 10:1, and co-cultured for 21 days. Thereafter, a Calcein AM release assay was performed, and lysis of K562 cells by NK cells was observed under a fluorescence microscope (zeiss microscope).

[0120] FIG. 9 shows results of examining cancer cell cytotoxicity of NK cells cultured by adding the composition for culturing NK cells of the present disclosure. The green-stained areas represent K562 cells. As shown in FIG. 9, as the ratio of NK cells (effectors) was higher, the number of live K562 cells was lower. This result suggests that apoptosis of K562 cell may be caused by interaction between NK cells and K562 cells.

[0121] (3.3) Examination of Cancer Cell Cytotoxicity of NK Cells Cultured by Adding Composition for Culturing NK Cells2.

[0122] (3.3.1) Caspase-3 Immunoblot

[0123] For in vitro cytotoxicity test of NK cells cultured by adding the composition for culturing NK cells of the present disclosure, ovarian cancer cells and NK cells were cultured, and then activity and expression levels of caspase-3 in the ovarian cancer cells were examined.

[0124] Ovarian cancer cells (A2780, SKOV3) were dispensed at a density of 1×10.sup.5 cells in each well of a 6-well plate coated with poly-D-lysine, and on next day, 1×10.sup.5 of NK92 and NK cells of the present disclosure for cytotoxicity assay were cultured with the ovarian cancer cells for 3 hr. Then, the culture medium and NK cells were removed, and only the remaining ovarian cancer cells were collected, followed by cell lysis using a lysis buffer. The cell lysate was heated at 95° C. for 10 min, and then proteins were isolated by centrifugation at 13,000 rpm for 20 min. The obtained proteins were separated using SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the separated proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, Mass., USA). The PVDF membrane was incubated with 5% skim milk to block non-specific antibody binding. Subsequently, the PVDF membrane was reacted with a primary antibody, anti-caspase-3, and anti-actin at 4° C. overnight, respectively. On next day, primary antibody-bound PVDF membrane was reacted with a peroxidase-conjugated secondary antibody at room temperature for 1 hr. Protein bands were visualized and quantified using an enhanced chemiluminescence (ECL) kit system.

[0125] FIG. 10 shows results of examining activity, expression patterns, and expression levels of caspase-3 in cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure. With progression of apoptosis, a whole form of caspase-3 was decreased, and a cleaved form thereof was increased. As shown in FIG. 10, the cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure showed increased protein quantity of caspase-3 cleaved form, indicating a significant increase of cytotoxicity against cancer cells. Further, the expression level of caspase-3 cleaved form in cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure showed about 5% to about 10% increase, as compared with that of cancer cells co-cultured with NK92 cells.

[0126] (3.3.2) Caspase-3 Immunofluorescence Staining

[0127] Subsequently, apoptosis progression in cancer cells was examined.

[0128] Ovarian cancer cells (A2780, SKOV3) were dispensed on a chamber slide coated with poly-D-lysine, and on next day, the equal numbers of NK92 cells and NK cells of the present disclosure were cultured with the ovarian cancer cells for 3 hr, respectively. The culture medium and NK cells were removed, and the remaining ovarian cancer cells were subjected to immunofluorescence staining. As a primary antibody, anti-caspase3 and anti-actin were used, and as a secondary antibody, Alexa 488 goat anti-rabbit and Alexa 546 goat anti-mouse were used. Actin and DAPI were used as controls. After staining, the slide was mounted, and observed under a confocal laser-scanning microscope.

[0129] FIG. 11 shows images of expression levels and expression locations of caspase-3 in cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure.

[0130] As shown in FIG. 11, the cancer cells which were co-cultured with NK cells cultured by adding the composition for culturing NK cells of the present disclosure showed about 50% or more increase in the caspase-3 activity, as compared with the control, and about 10% or more increase in the caspase-3 activity, as compared with cancer cells co-cultured with NK92 cells as another control.